|
FY2026
12 months to Mar 31, 2026
|
FY2025
12 months to Mar 31, 2025
|
FY2024
12 months to Mar 31, 2024
|
FY2023
12 months to Mar 31, 2023
|
FY2022
12 months to Mar 31, 2022
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash provided by operating activities: | |||||
| Depreciation and amortization | |||||
| Allowance for credit losses | |||||
| Amortization of debt discount, issuance costs, and exit and duration fees | |||||
| Loss on extinguishment of debt | |||||
| Provision for credit losses on accounts receivable | |||||
| Unrealized gain on derivatives | |||||
| Stock-based compensation expense | |||||
| Foreign exchange transaction gain | |||||
| Change in fair value of contingent consideration | |||||
| Total change in fair value of contingent consideration | |||||
| Non-cash lease expense | |||||
| Change in deferred income taxes | |||||
| Impairment of goodwill | |||||
| Changes in operating assets and liabilities: | |||||
| Accounts receivable | |||||
| Prepaid expenses | |||||
| Value-added tax receivable | |||||
| Other current assets | |||||
| Right-of-use assets | |||||
| Other non-current assets | |||||
| Accounts payable | |||||
| Accrued revenue share | |||||
| Accrued compensation | |||||
| Other current liabilities | |||||
| Other non-current liabilities | |||||
| Net cash provided by operating activities | |||||
| Cash flows from investing activities | |||||
| Equity investments | |||||
| Business acquisition, net of cash acquired | |||||
| Capital expenditures | |||||
| Net cash used in investing activities | |||||
| Cash flows from financing activities | |||||
| Proceeds from borrowings, net of original issue discount | |||||
| Payment of debt issuance costs | |||||
| Payment of deferred business acquisition consideration | |||||
| Repayment of debt obligations | |||||
| Acquisition of non-controlling interest in consolidated subsidiaries | |||||
| Proceeds from issuance of common stock in connection with at-the-market offering, net of issuance costs of $1,757 | |||||
| Payment of withholding taxes for net share settlement of equity awards | |||||
| Proceeds from options exercised | |||||
| Net cash provided by (used in) financing activities | |||||
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | |||||
| Net change in cash, cash equivalents, and restricted cash | |||||
| Cash, cash equivalents, and restricted cash, beginning of period | |||||
| Cash, cash equivalents, and restricted cash, end of period | |||||
| Supplemental disclosure of cash flow information | |||||
| Interest paid | |||||
| Income taxes paid | |||||
| Supplemental disclosure of non-cash investing and financing activities | |||||
| Assets acquired not yet paid | |||||
| Right-of-use assets acquired under operating leases | |||||
| Common stock issued for the acquisition of Fyber | |||||
| Unpaid cash consideration for the acquisition of Fyber Minority Interest | |||||
| Stock-based compensation included in capitalized software development costs | |||||
| Fair value of unpaid contingent consideration in connection with business acquisitions | |||||
| Reconciliation of cash, cash equivalents, and restricted cash | |||||
| Cash and cash equivalents | |||||
| Restricted cash | |||||
Loading...